

**Auditor's Report and  
Audited Financial Statements**

**Of**

**Silva Pharmaceuticals Limited**

**For the year ended June 30, 2025**

**Auditors**



**MZ Islam & Co.**  
Chartered Accountants



*An International Affiliated Member Firm of  
MGM Accountants Pty Ltd. Australia*

---

Chamber: 10 (4-7), Eastern View (10<sup>th</sup> Floor) 50, DIT Ext. Road, Nayapaltan, Dhaka-1000.  
TEL: 88-02-48310365, 88-02-222220092 E-mail: mzislam.ca@gmail.com

## Table of Contents

SL No.	Particulars	Page No.
1	Auditor's Report	1-5
2	Statement of Financial Position	6
3	Statement of Profit or Loss and other Comprehensive Income	7
4	Statement of Changes in Equity	8
5	Statement of Cash Flows	9
6	Notes to the Financial Statements	10-43
7	Annexure - A	44-45
8	Annexure - A/1	46-47
9	Annexure - B	48
10	Annexure - C	49



**Independent Auditors' Report  
To the Shareholders of  
Silva Pharmaceuticals Limited  
Report on the Audit of the Financial Statements**

**Qualified Opinion**

We have audited the financial statements of Silva Pharmaceuticals Limited, which comprise the statement of financial position as at June 30, 2025 and the Statement of Profit or Loss and other Comprehensive Income, statement of changes in equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matter described in the Basis for **Qualified Opinion** section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at June 30, 2025 and its financial performance and its cash flows for the year then ended in accordance with International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations.

**Basis for qualified opinion**

The company maintains an approved Provident Fund in accordance with Section 264 of the Bangladesh Labor Act, 2006. However, we noted that the related provisions and fund transfers have not been fully maintained in line with the applicable rules governing the approved fund. Certain deductions from employees' salaries and corresponding employer contributions were not fully deposited into the fund on a timely basis, and a complete reconciliation between the company records and the Provident Fund balances was not available for our review. As a result, we were unable to verify the completeness and accuracy of the Provident Fund liabilities and related disclosures in the financial statements notes 20.00.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountant (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our **qualified** opinion.

**Key Audit Matters**

Key Audit Matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.





Risks	Our response to the risks
<b>Revenue recognition</b>	
<p>At the year end the company reported total revenue of Tk. 383,648,446. Revenue is measured at contract value. Sales income is the major source of income for the company. Therefore, there is a risk of revenue being misstated.</p> <p>There is also a risk that revenue may be overstated due to fraud through manipulation and management may feel to achieve performance targets.</p> <p>See note no. 21 to the financial statements</p>	<p>We have tested the design and operative effectiveness of key controls focusing on the following:</p> <ul style="list-style-type: none"> <li>• Check controls over taking sales orders;</li> <li>• Segregation of duties in invoice creation and modification; and</li> <li>• Timing of revenue recognition.</li> </ul> <p>Our substantive procedures in relation to the revenue recognition comprises the following:</p> <ul style="list-style-type: none"> <li>• Obtaining supporting documentation for sales transactions recorded either side of year end to determine whether revenue was recognized in the correct period;</li> <li>• Cross match sales order, sales invoice and dispatch carefully;</li> <li>• Cross checking with Mushak 9.1; and</li> <li>• Critically assessing journals posted to revenue to identify unusual or irregular items.</li> </ul>
<b>Property, Plant and Equipment</b>	
<b>Inventories</b>	
<p>At year end the company reported total Inventories of Tk. 443,011,615.</p> <ul style="list-style-type: none"> <li>• This represent material amount of company's working capital in the financial statement as at June 30, 2025 as there is risk of uncollectible;</li> <li>• There is risk of overvaluation;</li> <li>• There is a risk of expiry of date of stocks.</li> <li>• There is a risk of damage of stocks.</li> </ul> <p>See note no. 8 to the financial statements</p>	<p>Our audit procedure to access the amount of inventories including the following:</p> <ul style="list-style-type: none"> <li>• Related staff of the company conducted physical inventories. We obtained the stated inventory report</li> <li>• Checking of cost sheet of finished product, checking of purchased price of raw materials.</li> </ul>
<b>Trade Receivable</b>	
<p>At year end the company reported total Receivable of Tk. 229,474,561. This represent material amount of company's working capital in the financial statement as at June 30, 2025 as there is risk of uncollectible;</p> <ul style="list-style-type: none"> <li>• There is risk of untraceable of credit parties which resulting bad debts.</li> </ul> <p>See note. 9.01 to the financial statements</p>	<p>Our audit procedure to access the amount of trade receivable including the following:</p> <ul style="list-style-type: none"> <li>• Checking of sales ledgers with DEPO wise sales statement.</li> <li>• Checking of subsequent collection amount.</li> <li>• Aging analysis.</li> <li>• Checking balance confirmation depo-wise.</li> </ul>





Measurement and recognition of deferred tax	
<p>The balance of reported deferred tax liability of the company was Tk. 81,270,136.</p> <p>Significant judgment is required in relation to deferred tax liability as their liability is dependent on forecast of future profitability over a number of years.</p> <p>The risk for financial statements is that these provisions are not properly measured for all types of temporary differences as per IAS 12 income tax.</p> <p>See note. 15.00 to the financial statements</p>	<p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the company's key control over the recognition and measurement of deferred tax assets and liabilities and assumptions used in estimating the future taxable expenses of the company. We also assess the completeness and accuracy of the data used for the estimation of future taxable expenses. We evaluated the reasonableness of key assumptions, timing of reversal of temporary differences and expiration of tax laws carry forwards, recognition and measurement of deferred tax liability. We assessed the adequacy of company's disclosures setting out the basis of deferred tax liability balances and the level of estimation involved. We also assisted in evaluating the tax implications, the reasonableness of estimates and calculations determined by the management.</p>

#### Other Information

Management is responsible for the other information. The other information comprises all of the information in the Annual report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. The annual report is expected to be made available to us after the date of this auditors' report.

In connection with our audit of the financial statements, our responsibility is to read the other information identifies above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance of the company.

#### Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the Financial Statements in accordance with related (IASs) and (IFRSs), and for such internal control as management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.





### Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatements, whether due to fraud or error and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatements of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusion is based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.


#### Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;
- c) The statements of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and
- d) The expenditure incurred was for the purpose of the Company's business.

Place: Dhaka  
Dated: October 28, 2025





  
**Mohammad Fakhruil Alam Patwary FCA**  
Enrollment No: 1249  
Managing Partner  
**M.Z. Islam & Co.**  
Chartered Accountants  
DVC: 2510281249AS441001


**Silva Pharmaceuticals Limited**  
**Statement of Financial Position**  
As at June 30, 2025

Particulars	Notes	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>ASSETS:</b>			
<b>Non Current Assets</b>		<b>1,422,482,307</b>	<b>1,474,712,706</b>
Property, Plant and Equipment	4.00	1,092,403,671	1,150,164,643
Intangible Assets	5.00	2,421,535	1,224,638
Right-of-use asset (ROU)	6.00	4,377,163	5,651,962
Capital work-in-Progress	7.00	323,279,938	317,671,463
<b>Current Assets</b>		<b>829,838,514</b>	<b>939,515,718</b>
Inventories	8.00	443,011,615	493,201,611
Trade and Other Receivables	9.00	229,617,998	256,130,421
Advances, Deposits and Prepayments	10.00	54,404,706	62,689,093
Fixed Deposits Receipts (FDR) with Banks	11.00	64,030,846	88,801,678
Cash and Cash Equivalents	12.00	38,773,349	38,692,915
<b>Total Assets</b>		<b>2,252,320,821</b>	<b>2,414,228,424</b>
<b>SHAREHOLDERS EQUITY AND LIABILITIES:</b>			
<b>Equity attributable to the Shareholders</b>		<b>2,113,040,947</b>	<b>2,255,949,495</b>
Share Capital	13.00	1,365,000,000	1,365,000,000
Retained Earnings	14.00	748,040,947	890,949,495
<b>Non-Current Liabilities</b>		<b>83,580,827</b>	<b>84,114,522</b>
Deferred Tax Liabilities	15.00	81,270,136	80,678,988
Lease liabilities	16.00	2,310,691	3,435,534
<b>Current Liabilities</b>		<b>55,699,047</b>	<b>74,164,407</b>
Short Term Finance	17.00	28,219,737	47,709,074
Lease liabilities	16.00	1,066,472	1,182,428
Trade and Other Payables	18.00	9,971,279	7,162,713
Unclaimed Dividend Account	19.00	139,158	176,686
Provision for Expenses	20.00	16,302,401	17,933,506
<b>Total Liabilities</b>		<b>139,279,874</b>	<b>158,278,929</b>
<b>Total Equity &amp; Liabilities:</b>		<b>2,252,320,821</b>	<b>2,414,228,424</b>
<b>Net Assets Value (NAV) per share</b>	30.00	<b>15.48</b>	<b>16.53</b>
<b>Number of Shares used to compute NAV</b>		<b>136,500,000</b>	<b>136,500,000</b>

The accompanying Notes 1 to 44 form an integral part of these financial statements.

  
CEO (cc)

  
Director

  
Director

  
CFO

  
CS

Signed as per our separate report of same date.

Place: Dhaka  
Dated: October 28, 2025





  
**Mohammad Fakhru Alam Patwary FCA**  
Enrolment No. 1249  
Managing Partner  
**M. Z. Islam & Co.**  
Chartered Accountants  
DVC : 2510281249AS441001


**Silva Pharmaceuticals Limited**  
**Statement of Profit or Loss and other Comprehensive Income**  
**For the year ended June 30, 2025**

Particulars	Notes	Amount in Taka	
		June 30, 2025	June 30, 2024
Revenue from Net Sales	21.00	383,648,446	599,659,109
Cost of goods sold	22.00	(281,177,455)	(436,758,103)
<b>Gross Profit</b>		<b>102,470,991</b>	<b>162,901,006</b>
<b>Operating expenses</b>		<b>(223,480,900)</b>	<b>(211,149,096)</b>
Administrative Expenses	23.00	(43,974,024)	(40,556,478)
Selling & Distribution Expenses	24.00	(179,506,876)	(170,592,618)
<b>Operating Income</b>		<b>(121,009,909)</b>	<b>(48,248,090)</b>
Financial expenses	25.00	(4,563,069)	(4,467,057)
Interest and Other income	26.00	5,993,552	6,218,502
<b>Profit before WPPF and Welfare Fund</b>		<b>(119,579,426)</b>	<b>(46,496,645)</b>
Workers' Profit Participation and Welfare Fund (WPP&WF)	27.00	-	-
<b>Profit before Income Tax</b>		<b>(119,579,426)</b>	<b>(46,496,645)</b>
Income Tax Expenses		(13,371,972)	(17,988,169)
Current Tax Expenses	28.01	(12,780,824)	(15,164,444)
Deferred Tax Income /(Expenses)	28.02	(591,148)	(2,823,725)
<b>Net Profit after tax</b>		<b>(132,951,398)</b>	<b>(64,484,814)</b>
Other Comprehensive Income		-	-
<b>Total comprehensive income for the year</b>		<b>(132,951,398)</b>	<b>(64,484,814)</b>
Earnings per Share (EPS)	29.00	(0.97)	(0.47)
Number of Shares used to compute EPS		136,500,000	136,500,000

*The accompanying Notes 1 to 44 form an integral part of these financial statements.*

  
CEO (cc)

  
Director

  
Director


  
CFO

  
CS

*Signed as per our separate report of same date.*

Place: Dhaka  
Dated: October 28, 2025



  
**Mohammad Fakhru Alam Patwary FCA**  
Enrolment No. 1249  
Managing Partner  
**M. Z. Islam & Co.**  
Chartered Accountants  
DVC : 2510281249AS441001

**Silva Pharmaceuticals Limited**  
**Statement of Changes in Equity**  
**For the year ended June 30, 2025**

Particulars	Amount in Taka		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2024	1,365,000,000	890,949,495	2,255,949,495
Dividend for the year 2023-2024	-	(9,957,150)	(9,957,150)
Net profit after tax during the year	-	(132,951,398)	(132,951,398)
<b>Balance as at 30 June, 2025</b>	<b>1,365,000,000</b>	<b>748,040,947</b>	<b>2,113,040,947</b>


The Board of Directors of the Company has recommended no dividend for the shareholders in its 105th board meeting dated 28 October, 2025.

**For the year ended 30 June, 2024**


Particulars	Amount in Taka		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2023	1,365,000,000	969,084,309	2,334,084,309
Dividend for the year 2022-2023	-	(13,650,000)	(13,650,000)
Net profit after tax during the year	-	(64,484,814)	(64,484,814)
<b>Balance as at 30 June, 2024</b>	<b>1,365,000,000</b>	<b>890,949,495</b>	<b>2,255,949,495</b>

The Board of Directors of the Company has recommended 01.00% cash dividend for all shareholders excluding Sponsor & Directors in its 101st board meeting dated 28 October, 2024.


*The accompanying Notes 1 to 44 form an integral part of these financial statements.*



CEO (cc)




Director



Director



CFO



*Signed as per our separate report of same date.*




**Silva Pharmaceuticals Limited**  
**Statement of Cash Flows**  
For the year ended June 30, 2025


Particulars	Notes	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>Cash flows from Operating Activities</b>			
Cash received from Customers	31.00	409,892,713	601,286,901
Cash received from non-operating income	32.00	6,261,708	7,779,674
Cash Paid to Suppliers	33.00	(147,779,104)	(359,323,211)
Cash Paid to Employees	34.00	(204,301,599)	(199,011,890)
Cash Paid for Others	35.00	(41,346,935)	(31,922,287)
Cash payment for Financial Expenses		(4,108,147)	(3,633,726)
Income Tax Paid	36.00	(5,060,573)	(11,756,646)
<b>Net cash generated from operating activities (A)*</b>	42.00	<b>13,558,063</b>	<b>3,418,815</b>
<b>Cash flows from Investing Activities</b>			
Acquisition of Property, Plant and Equipment	37.00	(1,460,250)	(2,787,445)
Cash Payments for Capital Work-in-progress		(5,608,475)	(30,202,279)
Cash received/Payments from/to FDR		24,770,832	63,922,944
<b>Net cash used in investing activities (B)</b>		<b>17,702,107</b>	<b>30,933,220</b>
<b>Cash flows from Financing Activities</b>			
Short Term Loan received/(Repaid)		(19,489,337)	(8,127,155)
Cash payment towards lease liabilities		(1,695,721)	(2,240,100)
Cash Dividend Paid		(9,994,678)	(13,934,477)
<b>Net cash used in financing activities (C)</b>		<b>(31,179,736)</b>	<b>(24,301,732)</b>
<b>Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)</b>		<b>80,434</b>	<b>10,050,303</b>
Cash and Cash Equivalents at the beginning of the year		38,692,915	28,642,612
<b>Cash and Cash Equivalents at the end of the year</b>	12.00	<b>38,773,349</b>	<b>38,692,915</b>
<b>Net Operating Cash Flow Per Share (NOCFPS)</b>	38.00	<b>0.10</b>	<b>0.03</b>
<b>Number of Shares used to compute NOCFPS</b>		<b>136,500,000</b>	<b>136,500,000</b>

\*Refer to Note 42.00 for a reconciliation between net profit with cash flows from operating activities.


The accompanying Notes 1 to 44 form an integral part of these financial statements.



CEO (cc)



Director



Director



CFO



Signed as per our separate report of same date.

## **Silva Pharmaceuticals Limited**

### **Notes to the Financial Statements**

**For the year ended June 30, 2025**

#### **1.00 About the Company**

##### **1.01 Formation and Legal Status**

Silva Pharmaceuticals Limited (the 'Company') was incorporated in Bangladesh on 24 April 2001 as a Private Limited Company and subsequently converted into Public Limited Company on 22 April, 2014 under the Companies Act, 1994 vide Registration No. CH-42959(2318)/2001 dated 24 April 2001. The Company went for Initial Public Offering (IPO) in 2018. The company is a publicly traded company and is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchanges Limited (CSE) since 10th October, 2018.

##### **1.02 Address of the Registered Office and Factory**

The registered and corporate office of the company is located at House # 65, Road No. 8/A (New), Dhanmondi, Dhaka-1209, Bangladesh.

Factory of the company is situated at 137, Joykrishnapur, Main Road, Maijdee Court, Noakhali.

##### **1.03 Nature of Business**

The Company is engaged in manufacturing and marketing of pharmaceuticals finished products in the categories of Antibiotics, Analgesics, Anti diabetics, Narcotics, Anti pyretic, Anti inflammatory Drugs, Anti ulcerants, Antiemetic, Gastroprokinetic, Anti histamine, Anti spasmodic expectorants, Vitamins & Minerals medicines which is selling mainly in local and international market.

#### **2.00 Basis of Preparation of Financial Statements**

##### **2.01 Presentation of Financial Statements**

The presentation of these financial statements is in accordance with the guidelines provided by International Accounting Standards (IAS)-1 "Presentation of Financial Statements". The Financial Statements includes the following components:

- i) The Statement of Financial Position as at 30 June, 2025;
- ii) The Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June, 2025;
- iii) The Statement of Changes in Equity for the year ended 30 June, 2025;
- iv) The Statement of Cash Flows for the year ended 30 June, 2025; and
- v) The Notes, comprising summary of significant accounting policies and other explanatory information.

##### **2.02 Statement of Compliance with Applicable Laws and Standards**

The Financial Statements have been prepared in accordance with International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council (FRC), Bangladesh, the Companies Act, 1994, the Bangladesh Securities and Exchange Rules, 2020, The Financial Reporting Act-2015, the Listing Regulation of Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) 2015 and other relevant laws as applicable.

The title and format of these financial statements follow the requirements of IFRSs which are to some extent different from the requirement of the Companies Act, 1994. However, such differences are not material and in the view of management, IFRS format gives a better presentation to the shareholders.

##### **2.03 Other Regulatory Compliance**

The Company also complied with the requirements of following laws and regulations from various Government bodies/regulations:



- The Income Tax Ordinance, 1984 and Income Tax Act, 2023
- The Income Tax Rules, 1984 & 2023
- The Value Added Tax and Supplementary Duty Act, 2012
- The Value Added Tax and Supplementary Duty Rules, 2016
- The Drug and Cosmetics Act, 2023
- The Financial Reporting Act, 2015 and FRC Notifications
- The Customs Act, 1969
- The Stamp Act, 1899
- The Bangladesh Securities and Exchange Commission Act, 1993
- The Bangladesh Securities and Exchange Commission Rules, 2020
- DSE and CSE Rules
- DSE & CSE (Listing) Regulations, 2015
- Bangladesh Labour Act, 2006 (As amended to 2018)

#### 2.04 Use of Estimates and Judgments

The preparation of financial statements in conformity with International Financial Reporting Standards (IFRS) requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors"

##### **Measurement of fair values**

A number of the Company's accounting policies and disclosures require the measurement of fair values for financial assets and liabilities.

The company has established solid internal control with respect to the measurement of fair values. Significant valuation issues are reported to Audit Committee.

When measuring the fair values of an asset or a liability, the company uses market observable data as per as possible. When one is available, the company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as 'active' if transactions for the assets or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no quoted price in an active market, then the company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

#### 2.05 Materiality, aggregation and off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the company has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of assets or liabilities as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

**2.06 Going Concern**

The financial statements of the Company have been prepared on a going concern basis. As per management assessment there are no material uncertainties related to events or conditions which may cast significant doubt upon Company's ability to continue as a going concern.

**2.07 Functional and Presentation Currency**

The financial statements are prepared and presented in Bangladesh Currency (Taka/ Tk./BDT), which is both functional and reporting currency of the Company.

**2.08 Reporting Period**

The financial statements of the Company consistently cover one financial year commencing from 01 July, 2024 to 30 June, 2025.

**2.09 Responsibility for the preparation and presentation of the financial statements**

The company's management and the Board of Directors are responsible for the preparation and presentation of Financial Statements as per section 183 of the companies Act 1994.

**2.10 Authorization for issuing Financial Statements**

The Financial Statements were authorized for issue by the Board of Directors in its meeting held on 28 October 2025 for publication.

**2.11 Accrual Basis of Accounting**

The Financial Statements have been prepared, except Cash Flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the company recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the IFRS conceptual Framework.

**2.12 Basis of Measurement**

The Financial Statements have been prepared on going concern basis under the historical cost convention except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

**2.13 Comparative and reclassification**

Comparative information has been disclosed in respect of previous year in accordance with IAS-1 "Presentation of Financial Statements" for all numeric information of the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year financial statements. Prior year figure has been rearranged/reclassified wherever considered necessary to ensure comparability with the current year financial statements.

**2.14 Application of Standards (IAS's)**

As per para 14 of the Securities and Exchange Rules 2020, the company complied with the following International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB) and subsequently adopted by the Financial Reporting Council (FRC) Bangladesh in preparing the financial statements.

Sl. No.	IAS/IFRS No.	Title of IAS/IFRS
<b>International Accounting Standards (IASs)</b>		
1	1	Presentation of Financial Statements
2	2	Inventories
3	7	Statement of Cash Flows
4	8	Accounting Policies, Changes in Accounting Estimates and Errors

5	10	Events after the Reporting period
6	12	Income Taxes
7	16	Property, Plant & Equipment
8	19	Employee Benefits
9	21	The Effects of Changes in Foreign Exchange Rates
10	23	Borrowing Costs
11	24	Related Party Disclosures
12	32	Financial instruments: Presentation
13	33	Earnings Per Share
14	34	Interim Financial reporting
15	36	Impairment of assets
16	37	Provisions, Contingent Liabilities and Contingent Assets
17	38	Intangible Assets
<b>International Financial Reporting Standards (IFRSs)</b>		
18	7	Financial Instruments: Disclosure
19	8	Operating Segments
20	9	Financial Instruments
21	13	Fair Value Measurement
22	15	Revenue from Contracts with Customers
23	16	Leases

### 3.00 Significant Accounting Policies

#### 3.01 Property, Plant and Equipment (PPE)

##### i) Recognition and Measurement

An item shall be recognized as Property, Plant and Equipment's (PPE) if, and only if it is probable that future economic benefits associated with the item will flow to the entity, and the cost of the item can be measured reliably.

In compliance with the IAS 16 "Property, Plant and Equipment" items of Property, Plant & Equipment (PPE) excluding land are initially measured at cost less accumulated depreciation and accumulated impairment losses, if any. Land is measured at cost. The cost of an item of PPE comprises its purchase price, import duties and non-refundable taxes after deducting trade discount and rebates and any costs directly attributable to bringing the assets to the location and condition necessary for it to be capable operating in the intended manner. The cost also includes the cost of replacing part of the property, plant & equipment and borrowing costs for term debt availed for the construction / implementation of the PPE, if the recognition criteria are met. The cost of self-constructed assets includes the cost of material and direct labour and other cost directly attributable to bringing the assets to a working condition inclusive of inward freight, duties and non-refundable taxes for their intended use.

##### ii) Subsequent Costs

The subsequent expenditure is only capitalized as part of assets when the useful life or economic benefit or both of that asset is increased provided that it is provable that the future economic benefits embodied within the part will flow to the company and its cost can be measured reliably. The cost of the day to day maintaining cost on PPE are recognized in the Statement of Profit or Loss and Other Comprehensive Income as incurred.

### iii) Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives. Depreciation has been charged on item of property, plant and equipment except land and land development is recognized in the statement of profit or loss and other comprehensive income using "Reducing Balance Method" over the estimated useful lives of each items.

Depreciation on addition to fixed assets charged when the assets are available for use i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended by the management.

Rate of depreciation on property, plant and equipments considering their useful lives are as follows:

Category of Fixed Assets	Rate of Depreciation
Plant & Machinery	10%
Generator	10%
Building Decoration	10%
Electrical Installation	10%
Gas Installation	10%
Office Equipment	10%
Factory Equipment	10%
Furniture and Fixture	10%
Vehicles	20%
Power House	10%
Laboratory Equipment	10%
Factory Building & Warehouse	2.50%

### iv) Retirement and Disposals

An asset is de-recognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of asset under other income in the statement of comprehensive income.

#### Impairment

The company reviews the recoverable amount of its assets at each reporting date. If there exist any indication that the carrying amount of assets exceeds the recoverable amount, the company recognizes such impairment loss in accordance with IAS-36 "Impairment of Assets".

All assets have been reviewed according to IAS-36 and it was confirmed that no such assets have been impaired during the year and for this reason no provision has been made for impairment of assets.

### 3.02 Capital work in progress

Property, Plant and Equipment under construction / acquisition have been accounted for as Capital work-in-progress until construction / acquisition is completed and measures at cost. In case of import, capital work in progress is recognized when risks and rewards associated with such assets are transferred to the company.

### 3.03 Intangible assets and research and development expenditures

Intangible assets are stated at cost less provisions for amortization and impairments, if any. License, patents, know-how and marketing rights acquired are amortized over their estimated useful lives, using the straight line basis, from the time they are available for use. The cost of acquiring and developing computer software for internal use and internet sites for external use are capitalized as intangible assets where the software or site supports a significant business system and the expenditure leads to the creation of a durable asset.

In compliance with the requirements of IAS 38 "Intangible Assets", research, development and experimental costs are usually absorbed as revenue charges as and when incurred. However, the research and development expenditures that is definite to yield benefit to the Company and is material in the Company's and/ local context, are capitalized as per IAS-38.

### 3.04 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds as per IAS 23: Borrowing Costs.

### 3.05 Inventories

Inventories are stated at the lower of cost or net realizable value in accordance with the Para of 21 & 25 of IAS-2 "Inventories". Costs including an appropriate portion of fixed and variable overhead expenses are assigned inventories by the method most appropriate to the particular class of inventory. Net Realizable Value represents the estimated selling price for the inventories less all estimated cost of completion and cost necessary to make the sale. Item wise valuation is as follows:

- i) Raw and packing materials at weighted average cost ;
- ii) Work-in-progress at standard cost;
- iii) Finished goods at lower of cost or net realizable value;
- iv) Spare & Tools and Printing & Stationary are at cost.

Standard cost comprises value of materials, standard activity cost and overheads.

### 3.06 Financial Instruments

IFRS 9 sets out requirements for recognizing and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items. This standard replaces IAS 39 Financial Instruments: Recognition and Measurement.

A financial instrument is any contract that gives rise to financial assets and a financial liability or equity instrument of another entity.

#### I. Financial Assets

##### (a) Investment in fixed deposit receipt

Fixed deposit, comprising funds held with banks and other financial institutions, are initially measured at fair value, plus direct transaction costs, and are subsequently measured at amortized cost using the effective interest method at each reporting date. Changes in carrying value are recognized in profit.

##### (b) Trade and Other Receivables

Trade receivables represents amount due from customers arising from transactions in the ordinary course of business. Other receivable amount consists of any other types of due from different parties. Aging calculation is prepared to assess the probability of non- recovery of any receivables.

Both receivables are initially recognized at original invoice/face value and subsequently assessed for recoverability and reported accordingly. The management contentiously assess whether provision for bad debt is required and if needed, will account for it.

##### (c) Advances, Deposits and Prepayments

Advances are recognized initially at actual cost and deductions or adjustments are accounted for on a timely and suitable manner.

Deposits are payments made for specific purposes which are expected to be realized or recovered in due course.

After initial recognition at cost, prepayments are carried at cost less the amount charged for respective periods.

(d) **Cash and cash equivalents**

Cash and cash equivalents consists of cash on hand and with banks on current accounts, deposit accounts and short term investments which are held and available for use by the company without any restriction. There is insignificant risk of change in value of the same.

II. **Financial Liabilities**

(a) **Borrowings**

All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the statement of profit or loss and other comprehensive income over the period of the relevant borrowing.

(b) **Trade and Other Payables**

Trade payables include amounts due to suppliers and other relevant parties in relation to the operating activities while other payables consist of amount payable to all the other parties not directly related to the operation of the company. These payables are recognized initially at fair value less any directly attributable transaction costs and subsequently measured at amortized cost using effective interest method.

3.07 **Changes in significant accounting policies**

The Company has consistently applied the accounting policies to all periods presented in these financial statements.

3.08 **Leases**

IFRS 16 introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months unless the underlying asset is of low value. A lessee is required to recognize a right-of-use asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments.

The Company entered into lease agreements with lessors to use building floor space for business purposes. It does not includes any Machinery, Copy Right, Software, Vehicles etc. The contracts don't offer any buying option, commitment to buy or any assurance of post use minimum market price for the used floors. Considering exemptions allowed in IFRS-16 (shorter contract tenor and small amount of rental expenses in respect to total revenue, the rental agreements) are not considered as finance lease.

(a) **Lease Assets (Right of Use Of Assets)**

The right of use asset is initially measured at the amount of the lease liability plus any initial direct costs incurred by the lessee. Adjustments may also be required for lease incentives, payments at or prior to commencement and restoration obligations or similar. Depreciation have charged on right to use assets on straight line basis over the lease period.

(b) **Lease Liabilities**

The lease liability is initially measured at the present value of the lease payments payable over the lease term, discounted at the rate implicit in the lease if that can be readily determined. If that rate cannot be readily determined, the lessee shall use their incremental borrowing rate.

3.09 **Provisions**

Provisions are recognized in the financial statements in line with the International Accounting Standards (IAS)-37 "Provisions, Contingent liabilities and Contingent Assets" when-

- i) The company has a legal constructive obligation as a result of past events.
- ii) It is probable that an outflow of economic benefit will be required to settle the obligations.
- iii) A reliable estimate can be made of the amount of the obligations.

The Company has no contingent liabilities & assets as per IAS 37 as on 30 June, 2025.

### 3.10 Related Party Disclosures

As per International Accounting Standards IAS-24 "Related Party Disclosures", parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. The company carried out transactions in the ordinary course of business on an arm's length basis at commercial rates with its related parties which have been given in Note-43.00 of these Financial Statements.

### 3.11 Employees' Benefit

The company maintains defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds. Employees of the company are entitled to get the following benefits from the company.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19 Employee Benefits.

The company's employee benefits include the following

#### i) Short Term Employee Benefits

Short-term employee benefits include salaries, bonus etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

#### ii) Workers Profit Participation and Welfare Fund (WPP&WF)

The company makes an allocation of 5% on net profit after charging such contribution but before tax to this fund as per provisions of the Bangladesh Labour Act, 2006 (Amendment 2013) and is payable to the workers as define in the said Law.

#### iii) Provident Fund and Gratuity

The company has established contributory provident fund scheme. The fund is wholly administered by a Board of Trustees. No part of the fund is included in the assets of the company. The fund is recognised by NBR.

### 3.12 Revenue Recognition

The Company recognizes as revenue the amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services when (or as) it transfers to the customer. To achieve that core principle this standard establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocation the transaction price to the performance obligations in the contracts; and
- Recognize revenue when (or as) the entity satisfies a performance obligation.

Considering the five step model the company recognizes revenue when (or as) the company satisfies a performance obligation by transferring a promise goods to a customer. Goods is considered as transferred when (or as) the customer obtains control of that goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).



**(a) Sale of Goods**

Revenue from sale of Goods is recognized when control of the goods and services are transfer to the customer at an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods. The company has generally concluded that it is the principal in its revenue arrangements because it typically controls the goods or services before transferring them to the customer.

**(b) Interest and Dividend Income**

Interest Income is recognized when accrued on a time proportion basis. Dividend income from an investment is recognized when the company's right to receive the payments is established, which is generally the date when shareholders approve the dividend.

**3.13 Income Taxes**

Income tax expenses comprised of current and deferred tax. Income tax expenses is recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted for in accordance with requirement of IAS-12 "Income Taxes".

**i) Current Tax**

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date and any adjustment to tax payable in respect of previous years. The tax rate used for the reporting period was 20.00% as a publicly traded company.

**ii) Deferred Tax**

The company has recognized deferred tax in compliance with the provision of IAS-12 "Income Taxes". The policy of recognition of deferred tax assets/liabilities is based on temporary differences (taxable or deductible) between the carrying amount (Book Value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income or expense has been considered to determine net profit after tax and Earnings Per Share (EPS).

**3.14 Segment Reporting**

As required by IFRS-8 "Operating Segments", if an entity operates and engages in different economic environments and activities then the entity has to disclose information, to enable users of its financial statements to evaluate the nature and financial effects of the business so carried out.

The company consider the operation on aggregate basis and manage the operations as a single operating segment. Hence it is felt that such segment reporting is not required to be disclosed.

**3.15 Contingent Liabilities and Assets**

Contingent liabilities and assets are current or possible obligations or assets, arising from past events and whose existence is due to the occurrence or non-occurrence of one or more uncertain future events which are not within the control of the company. In accordance with IAS-37 "Provisions, Contingent Liabilities and Contingent Assets" should not be recognized in the year in which the recognition criteria of provision have been made.

**3.16 Statement of Cash flows**

Statement of Cash Flows is prepared principally in accordance with IAS 7 "Statement of Cash Flows". The cash generating from operating activities has been reported using the direct method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS-7 whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.



### 3.17 Earnings Per Share (EPS)

Earnings Per Share (EPS) has been calculated in accordance with the International Accounting Standard IAS-33 "Earnings Per Share", by dividing the basic earnings by the weighted average number of ordinary shares outstanding during the year.

#### i) **Basic Earnings Per Share**

Basic earnings per share is calculated by dividing the profit or loss attributable to ordinary equity holders of the entity by the weighted average number of ordinary shares outstanding during the year. The basic EPS of previous year has been restated to adjust the effect of bonus issue of shares during the year. As there was no preference dividend, minority interest or extra ordinary items, the net profit after tax for the year has been considered as fully attributable to the ordinary shareholders.

#### ii) **Diluted Earnings Per Share**

For the purpose of calculating diluted earnings per share, an entity adjusts profit or loss attributable to each ordinary equity holders of the entity and weighted average number of shares outstanding, for the effects of all dilutive potential ordinary shares. Diluted EPS is only calculated where the company has commitment to issue ordinary share in future at reporting date. No such commitment is hold by the company at reporting date.

### 3.18 Financial Risk Management

International Financial Reporting Standard (IFRS) 7 - Financial instruments: Disclosures - requires disclosure of information relating to: both recognized and unrecognized financial instruments, their significance and performance, accounting policies, terms and conditions, net fair values and risk information- the Company's policies for controlling risks and exposures.

The management has overall responsibility for the establishment and oversight of the company's risk management framework. The company's risk management policies are established to identify and analyse the risks faced by the company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. This note presents information about the company's exposure to each of the following risks, the company's objectives, policies and processes for measuring and managing risk, and its management of capital. The company has exposure to the following risks from its use of financial instruments.

- a) Credit Risk
- b) Liquidity Risk
- c) Market Risk

#### a) **Credit Risk:**

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Credit risk information helps users of Financial Statements assess the credit quality of the entity's financial assets and level and sources of impairment loss. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis. As at 30 June 2024, a substantial part of the receivables is subject to insignificant credit risk. Risk exposures from other financial assets i.e. cash at the bank and other external receivables are very nominal.



**Management Perception:**

The senior management of Silva Pharmaceuticals Limited carefully manages its exposure to credit risk. Credit exposures arise principally in receivables from customers into Silva Pharmaceuticals Limited asset portfolio. The credit risk management and control are controlled through the credit policies of the company which are updated regularly. The company is also exposed to other credit risks arising from balances with banks which are controlled through board approved counterparty limits.

**b) Liquidity Risk:**

Liquidity risk is defined as the risk that the company will not be able to settle or meet its obligations on time or at a reasonable price.

**Management Perception:**

The company's approach toward managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

**c) Market Risk:**

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the company. Mostly, the risk arises from falling demand for the product or service which would harm the performance of the company. On the other hand, strong marketing and brand management would help the company increase their customer base.

**Management Perception:**

Management is fully aware of the market risk and act accordingly. Market for pharmaceuticals drugs and medicines in Bangladesh is growing at an exponential rate. Moreover, the company has a strong marketing and brand management to increase the customer base and customer loyalty.

**3.19 The Effects of Changes of Foreign Exchange Rates**

Foreign currency transactions are recorded at the rates applicable on the date of transaction in accordance with IAS-21 (The Effects of Changes in Foreign Exchange Rates). Gains or losses out of foreign currency transactions are charged/credited to the profit and loss account whenever arises. This year the company do not generate any revenue from export sale and the company imported raw materials and packing materials through sight L/C. Hence, no gain or losses arised from changes in foreign currency exchange rate. Monetary assets and liabilities in foreign currencies are converted into BDT at spot exchange rate at the reporting date.

**3.20 Events after the Reporting period**

As per IAS-10; Events after the reporting period that provide additional information about the company's position at the date of financial position are reflected in the financial statements. All material events occurring after the balance sheet date have been considered and where necessary, adjusted for or disclosed.

The Board of Directors of the Company has recommended no dividend for the shareholders in its 105th board meeting dated 28 October, 2025.

Except the facts and figures stated above, there is no other entry or note that has to be disclosed in the Financial Statements.



Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
4.00	<b>Property, Plant and Equipment</b>		
	<b>A) Cost</b>		
	Opening Balance	2,036,849,283	1,978,065,885
	Addition during the period	72,450	58,783,398
	Disposal/Transfer during the Year	-	-
	<b>Closing Balance</b>	<b>2,036,921,733</b>	<b>2,036,849,283</b>
	<b>B) Depreciation</b>		
	Opening Balance	886,684,640	827,896,459
	Charge during the period	57,833,422	58,788,181
	Disposal/Transfer during the Year	-	-
	<b>Closing Balance</b>	<b>944,518,062</b>	<b>886,684,640</b>
	<b>Written Down Value (A-B)</b>	<b>1,092,403,671</b>	<b>1,150,164,643</b>
	Details have been shown in Annexure-A		
5.00	<b>Intangible Assets</b>		
	<b>A) Cost</b>		
	Opening Balance	1,909,220	1,909,220
	Addition during the period	1,387,800	-
	Disposal/Transfer during the Year	-	-
	<b>Closing Balance</b>	<b>3,297,020</b>	<b>1,909,220</b>
	<b>B) Amortization</b>		
	Opening Balance	684,582	548,511
	Charge during the period	190,903	136,071
	Disposal/Transfer during the Year	-	-
	<b>Closing Balance</b>	<b>875,485</b>	<b>684,582</b>
	<b>Written Down Value (A-B)</b>	<b>2,421,535</b>	<b>1,224,638</b>
	Details have been shown in Annexure-B		
6.00	<b>Right of Use Assets (RoU)</b>		
	Opening Balance	26,266,197	26,266,197
	Less: Adjustment during the period	-	-
		<b>26,266,197</b>	<b>26,266,197</b>
	Less: Accumulated depreciation	21,889,034	20,614,235
	<b>Closing Balance</b>	<b>4,377,163</b>	<b>5,651,962</b>
	Details have been shown in Annexure-C		
7.00	<b>Capital Work in Progress</b>		
	<b>A) Construction work-in-progress (Building)</b>		
	Opening Balance	317,671,463	287,469,184
	Addition during the period	5,608,475	30,202,279
	<b>Closing Balance</b>	<b>323,279,938</b>	<b>317,671,463</b>
	<b>B) Plant and Machinery in transit and installation</b>		
	Opening Balance	-	55,995,953
	Addition during the period	-	-
	Transfer to Property, Plant and equipment	-	(55,995,953)
	<b>Closing Balance</b>	<b>-</b>	<b>-</b>
	<b>Total Closing Balance</b>	<b>323,279,938</b>	<b>317,671,463</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
	A new building is being constructed in the factory premises located at Binodpur, Sadar, Noakhali to increase the overall production capacity of The Silva Pharmaceuticals Limited. Capital Working-in-process expenditure include Tk. 6,05,32,650 out of Tk. 32,32,79,938 from use of IPO Fund under the head of construction of new factory building which have not start commercial production yet.		
<b>8.00</b>	<b>Inventories</b>		
	Raw Materials	256,370,266	305,261,325
	Packing Materials	36,672,514	37,463,562
	Spares & Tools	10,758,465	15,328,457
	Promotional Materials & Gift items	16,895,726	19,324,354
	Finished goods	105,874,652	109,462,185
	Work in Process-Closing	16,439,992	6,361,728
	<b>Total</b>	<b>443,011,615</b>	<b>493,201,611</b>

8.01 Physical verification of inventories was carried out by inventory team consisting management staffs and external auditors. Stock has been valued on the basis of valuation is stated in note-3.05.

**9.00 Trade and Other Receivable**

**Particulars**

Trade Receivables	Note- 9.01	229,474,561	255,718,828
Accrued Interest	Note- 9.02	143,437	411,593
<b>Closing Balance</b>		<b>229,617,998</b>	<b>256,130,421</b>

Trade receivables occurred in the ordinary course of business and are unsecured but considered good and recoverable within six months. The Accounts Receivables have no securities except their personal securities.

There was no amount due by the Directors (including Managing Director, Managing Agent, Manager and other Officers of the company) and any of them severally or jointly with any other person(s).

There was also no other amount due by associate undertakings.

**Ageing of the above Trade Receivables is given below**

Receivables due over six months	-	-
Receivables due below six months	229,474,561	255,718,828
<b>Total</b>	<b>229,474,561</b>	<b>255,718,828</b>

**9.01 Trade Receivable**

Barisal DMO	18,024,658	19,234,657
Bogra DMO	18,148,752	19,924,658
Chittagong DMO	19,534,655	23,619,455
Cumilla DMO	17,584,391	19,685,493
Dhaka DMO	18,542,356	21,876,342
Faridpur DMO	12,175,647	14,695,729
Jessore DMO	9,156,283	9,699,594

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
	Khulna DMO	-	3,649,752
	Bhairab DMO	13,836,287	15,346,136
	Mymensingh DMO	16,261,359	17,834,975
	Noakhali DMO	19,889,574	26,218,457
	Rajshahi DMO	15,791,251	16,327,458
	Dinajpur DMO	10,726,458	11,061,443
	Rangpur DMO	12,867,514	13,326,354
	Chandra DMO	4,848,275	2,138,561
	Cox's Bazar	5,619,842	3,725,486
	Sylhet DMO	16,467,259	17,354,278
	<b>Total</b>	<b>229,474,561</b>	<b>255,718,828</b>
<b>9.02</b>	<b>Accrued Interest</b>		
	Opening Balance	411,593	1,972,765
	Addition during the year	4,891,821	4,748,325
	<b>Total</b>	<b>5,303,414</b>	<b>6,721,090</b>
	Re-investment During the year	(2,586,584)	(3,295,953)
	Received/Encashment During the year	(2,573,393)	(3,013,544)
	<b>Closing Balance</b>	<b>143,437</b>	<b>411,593</b>
<b>10.00</b>	<b>Advances, Deposits and Prepayments</b>		
	<b>Advances &amp; Prepayments</b>		
	Advance Income Tax	Note- 10.01	5,060,573
	Advance against Purchase & Others		21,987,968
	Advance against L/C		9,756,116
	Advance against Travelling and Conveyance		2,640,738
	Advance against Motor-cycle Expenses		4,210,305
	Advance against Employee		1,853,740
	Advance against Depot Rent		1,905,600
	Prepayments of VAT		6,612,456
	<b>Total Advances and Prepayments</b>		<b>54,027,496</b>
	<b>Deposits</b>		
	<b>Security Deposit</b>		
	Bakhrabad Gas System Ltd		48,610
	Bangladesh T & T Board		40,600
	Power Development Board		288,000
	<b>Total Security Deposits</b>		<b>377,210</b>
	<b>Total</b>		<b>54,404,706</b>
			<b>62,689,093</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
	Advances: These advances are un-secured but good and subsequently realized and/or adjusted.		
	Deposits: These balances represents security deposits made by the company for Gas connection, Telephone line connection & Electricity connection etc.		
	There is no claim against the company, which can be acknowledge as debt.		
	There is no aggregate amount due from the Directors ( including Managing Director) and managing agents of the company and any of them severally or jointly with any other person.		
<b>10.01</b>	<b>Advance Income Tax</b>		
	Opening Balance	11,756,646	17,616,562
	Payment made during the year	5,060,573	11,756,646
	<b>Total</b>	<b>16,817,219</b>	<b>29,373,208</b>
	Adjustment made During the year	(11,756,646)	(17,616,562)
	<b>Closing Balance:</b>	<b>5,060,573</b>	<b>11,756,646</b>
<b>11.00</b>	<b>Fixed Deposits Receipts (FDR)</b>		
	Jamuna Bank Ltd. Foreign Exchange branch Dhaka	-	21,272,390
	Shahjalal Islami Bank Ltd. Satmosjid Road Branch, Dhaka.	64,030,846	67,529,288
	<b>Total</b>	<b>64,030,846</b>	<b>88,801,678</b>
<b>12.00</b>	<b>Cash and Cash Equivalents</b>		
	Cash in Hand at factory	5,670	36,739
	Cash in Hand at Head Office	10,057	33,286
	Cash in Hand at Depot Office	20,011,676	17,112,951
	Postal Imprest	3,065	3,065
	Cash at Bank	Note- 12.01	18,742,881
	<b>Total</b>	<b>38,773,349</b>	<b>38,692,915</b>
<b>12.01</b>	<b>Cash at Bank</b>		
	Al-Arafah Islami Bank Ltd. 0311020011891	211,660	117,093
	Al-Arafah Islami Bank Ltd. 0311220001386	56,822	16,219
	Dutch Bangla Bank Ltd. 1711100000380	745,479	3,927,561
	Dutch Bangla Bank Ltd. 1711200002165	45,989	5,608

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
	Dutch Bangla Bank Ltd. 2501200000282	438,059	62,515
	Dutch Bangla Bank Ltd. 7017700000272	-	498,152
	Dutch Bangla Bank Ltd. 1711200002688	46,675	64,137
	Dutch Bangla Bank Ltd. 1711200003141	109,276	127,251
	Dutch Bangla Bank Ltd. 1715290000052	2,544,064	2,479,594
	Dutch Bangla Bank Ltd. 1715270000142	10,951,375	10,728,386
	Dutch Bangla Bank Ltd. 1715270000158	1,078,701	1,058,908
	Dutch Bangla Bank Ltd. 1715270000163	1,078,700	1,058,908
	Dutch Bangla Bank Ltd. 1715280000036	1,084,736	1,060,539
	National Bank Ltd. 1063000829560	-	78,728
	Eastern Bank Ltd. 1063000829560	262,072	-
	Jamuna Bank Ltd. 00180210015437/ 1001000227878	36,571	59,711
	Union Bank Ltd. 0131210000536	2,911	4,146
	Sonali Bank Ltd. 441070200602	44,103	79,906
	Shahjalal Islami Bank Ltd. 401211100007640	1,830	74,233
	Shahjalal Islami Bank Ltd. 401213100009660	3,858	5,279
	<b>Total</b>	<b>18,742,881</b>	<b>21,506,874</b>
<b>13.00</b>	<b>Share Capital</b>		
<b>13.01</b>	<b>Authorized Share Capital</b>		
	15,00,00,000 ordinary shares of Tk 10/= each	<b>1,500,000,000</b>	<b>1,500,000,000</b>
<b>13.02</b>	<b>Issued, subscribed and paid-up share capital</b>		
(a)	<b>By Cash:</b>		
	13,00,00,000 Ordinary shares of Tk. 10/- each fully paid in cash	1,300,000,000	1,300,000,000
(b)	<b>By Issue of Bonus Share:</b>		
	65,00,000 Ordinary shares of Tk. 10/- each fully paid-up as bonus share:	65,000,000	65,000,000
	<b>Total 13,65,00,000 ordinary shares of Taka 10/= each.</b>	<b>1,365,000,000</b>	<b>1,365,000,000</b>



Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024

**Composition of Shareholdings of Ordinary Shares:**

Category of Shareholders	30-Jun-25		30-Jun-24	
	No. of Shares	%	No. of Shares	%
Sponsors/Directors	61,716,452	45.21%	69,539,201	50.94%
Financial and other Institutions	22,990,859	16.84%	21,866,686	16.02%
Foreign	11,025	0.01%	12,850	0.01%
General Public	51,781,664	37.94%	45,081,263	33.03%
<b>Total</b>	<b>136,500,000</b>	<b>100.00%</b>	<b>136,500,000</b>	<b>100.00%</b>

The Distribution Schedule showing the number of shareholders and their share holdings and percentage as on 30 June, 2024 are as follows:

Range of Holdings	No. of Shareholders	No. Of Shares	Percentage (%)
Less than 500 Shares	1,858	415,498	0.30%
From 501 to 5,000 Shares	3,141	5,766,517	4.22%
From 5,001 to 10,000 Shares	549	4,232,670	3.10%
From 10,001 to 20,000 Shares	327	4,897,663	3.59%
From 20,001 to 30,000 Shares	138	3,530,365	2.59%
From 30,001 to 40,000 Shares	63	2,198,890	1.61%
From 40,001 to 50,000 Shares	61	2,801,801	2.05%
From 50,001 to 1,00,000 Shares	92	6,680,727	4.89%
From 1,00,001 to 10,00,000 Shares	72	19,990,124	14.64%
From 10,00,001 and above Shares	22	85,985,745	62.99%
<b>Total</b>	<b>6,323</b>	<b>136,500,000</b>	<b>100.00%</b>

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock exchange Limited. The shares were quoted at Tk. 10.70 in the Dhaka stock Exchange Limited and Tk. 11.00 in the Chittagong Stock Exchange Limited as on 30.06.2024.

**14.00 Retained Earnings**

Opening balance	890,949,495	969,084,309
Dividend for the year 2023-2024 (1% Cash other than sponsors and directors)	(9,957,150)	(13,650,000)
Net profit after tax during the year	(132,951,398)	(64,484,814)
<b>Closing Balance</b>	<b>748,040,947</b>	<b>890,949,495</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024

**15.00 Deferred Tax Liabilities**

Deferred tax assets and liabilities have been recognised and measured in accordance with the provision of IAS 12 "Income Taxes". Related deferred tax expenses/income have been disclosed in note 28.02. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying Amount	Tax base value (*)	Taxable (deductible) Temporary Difference	Applicable tax rate	Deferred tax Liability
<b>As on 30 June, 2025</b>					
Property, Plant and Equipment	1,094,825,206	688,474,524	406,350,682	20.00%	81,270,136
<b>Total deferred tax liabilities for the year 2024-2025</b>	<b>1,094,825,206</b>	<b>688,474,524</b>	<b>406,350,682</b>		<b>81,270,136</b>
<b>30 June, 2024</b>					
Property, Plant and Equipment	1,151,389,281	747,994,342	403,394,939	20.00%	80,678,988
<b>Total deferred tax liabilities for the year 2023-2024</b>	<b>1,151,389,281</b>	<b>747,994,342</b>	<b>403,394,939</b>		<b>80,678,988</b>

(\*) The schedule of Tax base value of Property Plant and equipment are shown in Note 04(A) in this financial statements.

**16.00 Lease Liability**

Opening Balance	4,617,962	6,024,731
Finance Charge	454,922	833,331
Paid during the year	(1,695,721)	(2,240,100)
<b>Closing Balance</b>	<b>3,377,163</b>	<b>4,617,962</b>
Transferred to Current Maturity	(1,066,472)	(1,182,428)
<b>Non-Current Portion</b>	<b>2,310,691</b>	<b>3,435,534</b>

**17.00 Short Term Finance**

Outstanding position of Short Term Finance is shown below:

Jamuna Bank Limited SOD A/c. No. 6002000012105	-	18,602,881
SJIBL-BAI-MUAZZAL (FO)	12,912,624	14,390,343
DBBL, Account No. 1714050001188	15,307,113	14,715,850
<b>Total</b>	<b>28,219,737</b>	<b>47,709,074</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
18.00	<b>Trade and Other Payables</b>		
	<b>Particulars</b>		
	Alvi Enterprise	1,006,903	287,643
	Crystal Flexipack Ltd.	79,507	79,507
	Sun Shine Traders	37,661	287,661
	Rasayan Ghar	931,419	715,813
	JMS Glass Industries	210,976	135,026
	AGI Printing & Packaging Ltd.	1,139,808	652,534
	Dhaka Foil Corporation	500,477	442,829
	Reaz Enterprise	-	520,345
	Tanim Plastic Industries	304,375	526,330
	United Polymers Limited	348,450	348,450
	Index Chemi	2,176,888	698,312
	Mohd. Manik Miah Plastic	113,472	73,472
	Pharma Vintage	472,737	416,135
	Pharmacon Enterprise	544,150	203,500
	Bright International	111,000	311,000
	Shafin Trade Line	200,000	200,000
	World API Chemical Industry Limited	493,600	78,000
	Padma Blowing Ltd.	-	182,851
	Sonali Enterprise	332,970	336,720
	Mehedi Printing & Packaging	-	143,725
	CDM Accessories Ltd.	390,088	43,795
	CSI Trading & Corporation	-	479,065
	Zhaofeng Gelatin Ltd.	7,705	-
	Arafat Enterprise	94,134	-
	Rifat Plastic	474,959	-
	<b>Total</b>	<b>9,971,279</b>	<b>7,162,713</b>

This represents the amount payable to suppliers of raw materials, packing materials, Promotional materials etc. All suppliers were paid on a regular basis.

**19.00 Dividend Payable / Unclaimed Dividend**

Opening balance	176,686	461,163
Provision made during the Period	9,957,150	13,650,000
Interest (net off AIT & Bank charge)	140	(3,676)
<b>Total</b>	<b>10,133,976</b>	<b>14,107,487</b>
Paid during the year	(9,925,217)	(13,736,815)
Paid to Capital Market Stabilization Fund (CMSF) during the year	(69,601)	(193,986)
<b>Closing balance</b>	<b>139,158</b>	<b>176,686</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
	Year-wise break-up of Dividend payable is as follows:		
	For the year 2023-2024	35,347	-
	For the year 2022-2023	49,203	49,203
	For the year 2021-2022	39,875	39,875
	For the year 2020-2021	-	69,601
	Interest (net off AIT & Bank charge)	14,733	18,007
	<b>Total</b>	<b>139,158</b>	<b>176,686</b>
	NB: During the current financial year, the Company has transferred Tk. 69,601.00 of unclaimed cash dividends pertaining to the 2020-2021 fiscal year to the Capital Market Stabilization Fund (CMSF), in compliance with the Regulation 9 of the Bangladesh Securities and Exchange Commission (Capital Market Stabilization Fund) Rules, 2021.		
<b>20.00</b>	<b>Provision for expenses</b>		
	Directors Remuneration	-	100,000
	Field Forces Expenses	128,546	168,457
	Utilities	396,371	528,073
	Salary & Wages	5,074,355	6,510,361
	Audit, Legal & Professional Fees	3,380,750	2,889,460
	Overtime	26,735	47,386
	Staff Welfare expenses	756,912	1,603,167
	TDS Payable	68,826	640,874
	Worker's Profit Participation and Welfare Fund (WPP&WF)	Note- 20.01	-
	Provision for Income Tax	Note- 20.02	5,445,728
	<b>Total</b>	<b>16,302,401</b>	<b>17,933,506</b>
<b>20.01</b>	<b>Worker's Profit Participation and Welfare Fund (WPP&amp;WF)</b>		
	Opening balance	-	2,518,229
	Provision made during the year	-	-
	<b>Total</b>	-	<b>2,518,229</b>
	Paid during the year	-	(2,518,229)
	<b>Closing balance</b>	-	<b>-</b>
<b>20.02</b>	<b>Provision for Income Tax</b>		
	Opening balance	5,445,728	7,897,846
	Provision made during the year	12,780,824	15,164,444
	<b>Total</b>	<b>18,226,552</b>	<b>23,062,290</b>
	Paid/Adjustment made during the year	(11,756,646)	(17,616,562)
	<b>Closing balance</b>	<b>6,469,906</b>	<b>5,445,728</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>21.00</b>	<b>Revenue</b>		
	Net Sales	383,648,446	599,659,109
	<b>Total</b>	<b>383,648,446</b>	<b>599,659,109</b>
<b>22.00</b>	<b>Cost of goods sold</b>		
	Raw materials consumed	Note- 22.01 147,092,183	213,849,209
	Packing materials consumed	Note- 22.02 45,979,782	117,537,684
	Consumable item consumed	Note- 22.03 11,498,902	24,075,645
		<b>204,570,867</b>	<b>355,462,538</b>
	Work in process- Opening	6,361,728	6,357,249
	Work in process- Closing	(16,439,992)	(6,361,728)
	<b>Change in work in process</b>	<b>(10,078,264)</b>	<b>(4,479)</b>
	Manufacturing Overhead	Note- 22.04 34,769,259	35,230,823
	Depreciation	53,785,083	54,673,008
	<b>Cost of production</b>	<b>283,046,945</b>	<b>445,361,890</b>
	Finished goods - Opening	109,462,185	104,856,358
	Finished goods - Closing	(105,874,652)	(109,462,185)
	<b>Change of finished goods stock</b>	<b>3,587,533</b>	<b>(4,605,827)</b>
	Cost of Physician Sample	(5,457,023)	(3,997,960)
	<b>Cost of Goods Sold</b>	<b>281,177,455</b>	<b>436,758,103</b>
<b>22.01</b>	<b>Raw materials consumed</b>		
	Opening Stock	305,261,325	302,694,806
	Purchase during the year	98,201,124	216,415,728
	Available for production	<b>403,462,449</b>	<b>519,110,534</b>
	Closing Stock	(256,370,266)	(305,261,325)
	<b>Consumption during the year</b>	<b>147,092,183</b>	<b>213,849,209</b>
<b>22.02</b>	<b>Packing materials consumed</b>		
	Opening Stock	37,463,562	41,635,982
	Purchase during the year	45,188,734	113,365,264
	Available for Consumed	<b>82,652,296</b>	<b>155,001,246</b>
	Closing Stock	(36,672,514)	(37,463,562)
	<b>Consumption during the year</b>	<b>45,979,782</b>	<b>117,537,684</b>
<b>22.03</b>	<b>Consumable Spares &amp; Tools</b>		
	Opening Stock	15,328,457	17,342,850
	Purchase during the year	6,928,910	22,061,252
	Consumable Spares & Tools available	<b>22,257,367</b>	<b>39,404,102</b>
	Closing Stock	(10,758,465)	(15,328,457)
	<b>Consumption during the year</b>	<b>11,498,902</b>	<b>24,075,645</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>22.04</b>	<b>Manufacturing overhead</b>		
	Salary, Wages & Allowances	20,587,826	20,212,925
	Workers' benefit and welfare expense	526,336	553,935
	Overtime	383,210	734,468
	Staff Welfare expenses	641,511	733,044
	Laboratory Expenses	48,975	482,576
	Postage & Stamp	25,632	24,662
	Indirect materials	406,995	851,830
	Electricity Bill	3,734,951	4,070,866
	Gas & Water bill	210,216	268,782
	Uniform and liveries	67,415	54,435
	Carriage Inward	537,534	875,073
	Medical Expenses	20,000	31,385
	Power & Fuel	191,854	1,071,444
	Printing & Stationery	597,282	90,797
	Traveling & Conveyance	86,987	109,530
	Factory Rent	1,440,000	1,440,000
	Toll Charges	4,104,888	-
	Repairs & Maintenance	787,918	3,208,639
	Sanitation & Cleaning	71,670	207,152
	Entertainment	298,059	209,280
	<b>Total</b>	<b>34,769,259</b>	<b>35,230,823</b>
<b>23.00</b>	<b>Administrative Expenses</b>		
	Salary, Wages & Allowances	28,336,264	26,719,452
	Staff Welfare expenses	1,181,040	854,416
	Printing & Stationery	247,275	253,916
	Phone, Fax, Internet and Mobile Bill	567,458	485,520
	Postage & Stamps	68,934	66,572
	Traveling & Conveyance	1,052,367	175,888
	Utility Bill	923,880	890,002
	Entertainment	572,157	446,042
	Donation and Subscription	178,040	-
	Licenses Renewal and Registration Fee	245,880	419,615
	Audit Fees	402,500	402,500
	Directors Remuneration	500,000	1,200,000
	Board meeting attending fees	393,750	421,875
	Amortization of Intangible Assets	190,903	136,071
	Depreciation of Right-of-use Assets	1,274,799	1,658,433
	Depreciation	3,470,005	3,527,291
	Repairs & Maintenance	1,151,477	692,942
	RJSC Exp.	6,188	5,038
	AGM Expenses	464,998	249,730
	Legal & Professional fees	2,746,109	1,951,175
	<b>Total</b>	<b>43,974,024</b>	<b>40,556,478</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>24.00</b>	<b>Selling &amp; Distribution Expenses</b>		
	Salary, Wages & Allowances	122,523,744	126,030,068
	Field forces expenses	24,325,502	16,423,620
	Transportation & Handling Expenses	4,383,749	2,228,718
	Staff Welfare expenses	2,579,302	3,032,463
	Business Promotion Expenses	1,450,099	224,258
	Repair & Maintenance	646,051	394,485
	Traveling and conveyance Expenses	1,259,560	1,565,807
	Water, electricity and Gas	557,197	594,135
	Phone, Fax, Internet and Mobile Bill	530,272	444,100
	Sample Expenses	5,457,023	3,997,960
	Consumption of promotional materials	3,921,528	3,597,564
	Postage & Courier	944,063	1,179,349
	Entertainment	293,559	362,236
	Printing & Stationery	1,722,571	1,707,248
	Depot Rent	4,769,871	3,786,950
	Product Development Expenses	17,171	45,700
	Training Expenses	866,257	884,888
	Bank Charge	597,475	1,447,202
	Depreciation	578,334	587,882
	Vehicle Maintenance	1,599,290	1,508,347
	Loading & Unloading	280,484	341,572
	License fees & Renewals	203,774	208,066
	<b>Total</b>	<b>179,506,876</b>	<b>170,592,618</b>
<b>24.01</b>	<b>Promotional materials &amp; Gift Items</b>		
	Opening Stock	19,324,354	20,834,756
	Purchase during the year	1,492,900	2,087,162
	Available	<b>20,817,254</b>	<b>22,921,918</b>
	Closing Stock	(16,895,726)	(19,324,354)
	<b>Consumption during the year</b>	<b>3,921,528</b>	<b>3,597,564</b>
<b>25.00</b>	<b>Financial Expenses</b>		
	Interest on Short Term Loan	4,026,997	3,550,015
	Bank Charge & Commission	81,150	83,711
	Interest expenses on lease liabilities	454,922	833,331
	<b>Total</b>	<b>4,563,069</b>	<b>4,467,057</b>
<b>26.00</b>	<b>Other Income</b>		
	Interest on FDR	4,891,821	4,748,325
	Interest on Bank STD Accounts	445,416	422,044
	Miscellaneous Income	656,315	1,048,133
	<b>Total</b>	<b>5,993,552</b>	<b>6,218,502</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>27.00</b>	<b>Workers Profit Participation and Welfare Fund (WPPF&amp;WF)</b>		
	Net Profit before Contribution to WPPF&WF	(119,579,426)	(46,496,645)
	Rate of contribution to WPPF&WF(%)	5.00%	5.00%
	Workers Profit Participation and Welfare Fund (WPPF&WF)	-	-
	Note: Allocation for workers' profit participation and welfare fund has been made @ 5% of profit after charging such expenses as per provisions of the Bangladesh Labour Act, 2006 (Amendment 2013).		
<b>28.00</b>	<b>Income Tax expenses</b>		
<b>28.01</b>	<b>Current Tax Expenses</b>		
	Net Profit before Income Tax	(119,579,426)	(46,496,645)
	Accounting Depreciation	58,024,325	58,924,252
	Excess Perquisites	440,000	440,000
	Entertainment expenses	1,163,775	1,017,558
	Tax Depreciation	(60,980,068)	(73,042,878)
	Entertainment expenses as per tax law	-	-
	Excess Sample Expenses	2,538,781	-
	Excess Promotional Expenses	2,003,286	-
	<b>Taxable Profit</b>	<b>(116,389,327)</b>	<b>(59,157,713)</b>
	Tax Rate	20.00%	20.00%
	<b>Current Tax Expenses</b>	-	-
	<b>Minimum Tax Calculation</b>		
	<b>Calculation of Gross Receipts</b>		
	Revenue from net sales	383,648,446	599,659,109
	<b>Other Income</b>		
	Interest on FDR	4,891,821	4,748,325
	Interest on Bank deposit	445,416	422,044
	Other Income	656,315	1,048,133
	<b>Total Gross Receipts</b>	<b>389,641,998</b>	<b>605,877,611</b>
	<b>Minimum Tax Calculation</b>		
	1.00% on total gross receipts except Interest income	3,843,048	3,604,243
	AIT paid on Interest income and Vehicle (U/S -163)	2,626,858	1,841,485
	<b>Minimum Tax under section 163(5) of ITA 2023</b>	<b>6,469,906</b>	<b>5,445,728</b>
	<b>Income Tax Provision whichever is higher</b>	<b>6,469,906</b>	<b>5,445,728</b>
	Current Tax Expenses for the previous Assessment year	6,310,918	9,718,716
	<b>Total Current Tax Expenses</b>	<b>12,780,824</b>	<b>15,164,444</b>

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 (6) of Income Tax Act, 2023. Hence the minimum tax is accounted for as it is higher than the tax at regular rate.



Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
28.02	<b>Deferred Tax Expenses/(Income)</b>		
	Closing balance of deferred tax liability	Note- 15 81,270,136	80,678,988
	Opening balance of deferred tax liability	Note- 15 (80,678,988)	(77,855,263)
	<b>Deferred Tax Expenses/(Income)</b>	<b>591,148</b>	<b>2,823,725</b>
29.00	<b>Earnings Per Share(EPS)</b>		
	Net Profit after taxes	(132,951,398)	(64,484,814)
	Weighted average number of ordinary share	136,500,000	136,500,000
	<b>Earnings per share (Diluted)</b>	<b>(0.97)</b>	<b>(0.47)</b>

Earnings Per Share (EPS) has been computed by dividing the basic earning by the weighted average number of ordinary shares outstanding at the end of the year as per IAS 33 Earnings Per Share.

#### Weighted average number of ordinary shares outstanding during the year

This represents the number of ordinary shares outstanding at the beginning of the year plus the number of ordinary shares issued during the year multiplied by the weighted factor.

#### Diluted earnings per share

The objective of diluted earnings per share is consistent with that of basic earnings per share; that is, to provide a measure of the interest of each ordinary shares in the performance of an entity taking into account dilutive potential ordinary shares outstanding during the year. Diluted EPS is only calculated where the company has commitment to issue ordinary share in future at reporting date. No such commitment is hold by the company at this reporting date.

#### 29.01 Weighted average number of Ordinary Shares Outstanding

Particulars	No. of Shares	Days	Weight	Weighted Average No. of Shares	
				30-Jun-25	30-Jun-24
Opening balance	130,000,000	365	1.0000	130,000,000	130,000,000
Issued Bonus Share (06.11.2019)	6,500,000	365	1.0000	6,500,000	6,500,000
<b>Total</b>	<b>136,500,000</b>			<b>136,500,000</b>	<b>136,500,000</b>

#### 30.00 Net Asset Value (NAV) Per Share

	Amount in Taka	
	June 30, 2025	June 30, 2024
Total Assets	2,252,320,821	2,414,228,424
Less: Total Liabilities	139,279,874	158,278,929
<b>Net Asset Value</b>	<b>2,113,040,947</b>	<b>2,255,949,495</b>
Total Number of Shares outstanding	136,500,000	136,500,000
<b>Net Asset Value (NAV) Per Share</b>	<b>15.48</b>	<b>16.53</b>

Net asset value per share (NAV) has been computed by dividing total assets by the number of ordinary shares outstanding as on 30 June 2025 as per Notification of Bangladesh Securities & Exchange Commission (BSEC).

#### 31.00 Cash received from Customers

	Amount in Taka	
	June 30, 2025	
Sales during the year	383,648,446	599,659,109
Opening Trade Receivable	255,718,828	257,346,620
Closing Trade Receivable	(229,474,561)	(255,718,828)
<b>Total Cash Received from Customers</b>	<b>409,892,713</b>	<b>601,286,901</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>32.00</b>	<b>Cash received from non-operating income</b>		
	Other income	5,993,552	6,218,502
	Opening interest receivable	411,593	1,972,765
	Closing interest receivable	(143,437)	(411,593)
	<b>Total Cash received from non-operating income</b>	<b>6,261,708</b>	<b>7,779,674</b>
<b>33.00</b>	<b>Cash Paid to Suppliers</b>		
	Purchase (Raw, Packing, Promotional, Indirect material and Spare	152,218,663	354,781,236
	Opening Accounts Payable	7,162,713	6,989,159
	Closing Accounts Payable	(9,971,279)	(7,162,713)
	Closing Advance against Purchase & L/C	31,744,084	33,375,077
	Opening Advance against Purchase & L/C	(33,375,077)	(28,659,548)
	<b>Total Cash Paid to Suppliers</b>	<b>147,779,104</b>	<b>359,323,211</b>
<b>34.00</b>	<b>Cash Paid to Employees</b>		
	Salary, Wages & Allowances including Staff welfare expenses	175,849,687	177,582,368
	Workers' benefit and welfare expense	526,336	553,935
	Overtime	383,210	734,468
	Directors Remuneration	500,000	1,200,000
	Board meeting attending fees	393,750	421,875
	Field forces expenses	24,325,502	16,423,620
	Worker's Profit Participation and Welfare Fund	-	2,518,229
	Opening Liabilities for Expenses	8,429,371	7,905,969
	Closing Liabilities for Expenses	(5,986,548)	(8,429,371)
	Closing Advance to Employee	1,853,740	1,973,449
	Opening Advance to Employee	(1,973,449)	(1,872,652)
	<b>Total Cash Paid to Employees</b>	<b>204,301,599</b>	<b>199,011,890</b>
<b>35.00</b>	<b>Cash Paid for Others</b>		
	Manufacturing Overhead (excluding pay to employee & Supplier)	12,223,381	12,144,621
	Administrative Overhead (excluding Depreciation & pay to employee)	8,627,263	6,038,940
	Selling and Distribution overhead (excluding sample, promotional, Depreciation & pay to employee)	20,121,443	16,923,061
	Opening Liabilities for Expenses	4,058,407	3,158,955
	Closing Liabilities for Expenses	(3,845,947)	(4,058,407)
	Closing Advance deposit & prepayment	15,746,309	15,583,921
	Opening Advance deposit & prepayment	(15,583,921)	(17,868,804)
	<b>Total Cash Paid for Others</b>	<b>41,346,935</b>	<b>31,922,287</b>
<b>36.00</b>	<b>Income Tax paid</b>		
	Advance Income Tax paid	5,060,573	11,756,646
	<b>Total Income Tax paid</b>	<b>5,060,573</b>	<b>11,756,646</b>
<b>37.00</b>	<b>Cash payment for Acquisition of Property, Plant and Equipment (PPE)</b>		
	Property, Plant and Equipment addition during the year	1,460,250	58,783,398
	Addition from Capital Work-in-Progress	-	(55,995,953)
	<b>Total Cash payment for Acquisition PPE</b>	<b>1,460,250</b>	<b>2,787,445</b>

Notes	Particulars	Amount in Taka	
		June 30, 2025	June 30, 2024
<b>38.00</b>	<b>Net Operating Cash Flow Per Share(NOCFPS)</b>		
	Net Operating Cash Flow	13,558,063	3,418,815
	Weighted Average Number of Shares Outstanding	136,500,000	136,500,000
	<b>Net Operating Cash Flows Per Share(NOCFPS)</b>	<b>0.10</b>	<b>0.03</b>
	Net operating cash flow per share (NOCFPS) has been computed by dividing net operating cash flow by the number of ordinary shares outstanding as on 30 June 2025 as per Notification of Bangladesh Securities & Exchange Commission (BSEC).		
<b>39.00</b>	<b>Revenue from contracts with customers</b>		
	The Company has recognized the following amount in the statement of profit and loss and other comprehensive income.		
	Revenue from contract with customer (Note no-21.00)	383,648,446	599,659,109
	Segregation of revenue from contracts with customer		
	Revenue from external customer	383,648,446	599,659,109
	Timing of revenue recognition at a point in time	383,648,446	599,659,109
	<b>Contract assets and liabilities</b>		
	The Company has recognized no contract assets and liabilities.		



**40.00 Financial instruments- fair value**  
**Accounting classifications and fair values**

The following table shows the carrying amounts and fair values of financial assets and financial liabilities. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a  
**June 30, 2025**

Particulars	Note	Carrying amount					Total
		Fair value hedging instruments	Mandatory at fair value	FVOC-debt instruments	Financial assets at amortized value	Other financial liabilities	
<b>Financial assets measured at fair value</b>							
		-	-	-	-	-	-
<b>Financial assets not measured at fair value</b>							
Trade receivables	9.01	-	-	-	229,474,561	-	229,474,561
Fixed Deposits Receipts (FDR) with Banks	11.00	-	-	-	64,030,846	-	64,030,846
Cash and cash equivalents	12.00	-	-	-	38,773,349	-	38,773,349
					<b>332,278,756</b>		<b>332,278,756</b>
<b>Financial liabilities measured at fair value</b>							
		-	-	-	-	-	-
<b>Financial liabilities not measured at fair</b>							
Short term loans	17.00	-	-	-	-	28,219,737	28,219,737
Trade payable	18.00	-	-	-	-	9,971,279	9,971,279
Lease liabilities	16.00	-	-	-	-	3,377,163	3,377,163
						<b>41,568,179</b>	<b>41,568,179</b>

**June 30, 2024**

Particulars	Note	Carrying amount					Total
		Fair value hedging instruments	Mandatory at fair value	FVOC-debt instruments	Financial assets at amortized value	Other financial liabilities	
<b>Financial assets measured at fair value</b>							
		-	-	-	-	-	-
<b>Financial assets not measured at fair value</b>							
Trade receivables	9.01	-	-	-	255,718,828	-	255,718,828
Fixed Deposits Receipts (FDR) with Banks	11.00	-	-	-	88,801,678	-	88,801,678
Cash and cash equivalents	12.00	-	-	-	38,692,915	-	38,692,915
					<b>383,213,421</b>		<b>383,213,421</b>
<b>Financial liabilities measured at fair value</b>							
		-	-	-	-	-	-
<b>Financial liabilities not measured at fair</b>							
Short term loans	17.00	-	-	-	-	47,709,074	47,709,074
Trade payable	18.00	-	-	-	-	7,162,713	7,162,713
Lease liabilities	16.00	-	-	-	-	4,617,962	4,617,962
						<b>59,489,749</b>	<b>59,489,749</b>



**41.00 Disclosure as per requirement of the Companies Act, 1994**
**41.01 Disclosure as per Schedule XI, part I, para 4 of the Companies Act, 1994 are given below:**

Sl. No.	Particulars	June 30, 2025	June 30, 2024
		Amount in Taka	
I	Receivables considered good and in respect of which the company is fully secured.	-	-
II	Receivables considered good for which the company holds no security other than the debtor's personal security.	229,474,561	255,718,828
III	Receivables considered doubtful or bad.	-	-
IV	Receivables due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Receivables due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	-	-
<b>Total:</b>		<b>229,474,561</b>	<b>255,718,828</b>

**41.02 Disclosure as per Schedule XI, part I, para 6 of the Companies Act, 1994 are given below:**

Sl. No.	Particulars	June 30, 2025	June 30, 2024
		Amount in Taka	
I	Advances, Deposits and Prepayments considered good and in respect of which the company is fully secured.	-	-
II	Advances, Deposits and Prepayments considered good for which the company holds no security.	45,699,923	53,480,403
III	Advances, Deposits and Prepayments considered doubtful or bad.	-	-
IV	Advances, Deposits and Prepayments due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, Deposits and Prepayment due by firms or private companies respectively in which any director is a partner or a director or a member.	-	-
V	Advance, Deposits and Prepayment due by companies under the same management.	-	-
VI	The maximum amount due by directors or other officers of the company at any time during the year.	8,704,783	9,208,690
<b>Total:</b>		<b>54,404,706</b>	<b>62,689,093</b>



**41.03 Disclosure of Schedule XI, Part II, Para 3, of the Companies Act, 1994 are given below:**
**I. a. Turnover:**

Particulars	June 30, 2025		June 30, 2024	
	Quantity (Pcs/PHs)	Amount in Taka	Quantity (Pcs/PHs)	Amount in Taka
Tablet	58,886,361	233,806,610	91,864,525	278,464,528
Capsule	4,966,244	23,326,660	24,919,458	108,275,846
Liquid	725,284	74,749,838	1,384,750	88,246,250
Dry Syrup	328,298	51,765,338	1,252,245	124,672,485
<b>Total</b>	<b>64,906,187</b>	<b>383,648,446</b>	<b>119,420,978</b>	<b>599,659,109</b>

b. No Commission paid to selling agents during the year.

c. No brokerage and discount paid on sales, other than the usual trade discount during the year.

d. (i) Raw Materials consumed:

Particulars	30-Jun-2025		June 30, 2024	
	R M (Kg)	Amount in Taka	R M (Kg)	Amount in Taka
Opening stock	210,168	305,261,325	278,540	302,694,806
Purchase	185,869	98,201,124	176,441	216,415,728
Raw material available for consumption	<b>396,037</b>	<b>403,462,449</b>	<b>454,981</b>	<b>519,110,534</b>
Closing stock	(158,299)	(256,370,266)	(210,168)	(305,261,325)
<b>Raw material consumed</b>	<b>237,738</b>	<b>147,092,183</b>	<b>244,813</b>	<b>213,849,209</b>

(ii) Finished goods:

Classes of Goods	June 30, 2025			June 30, 2024		
	Opening Qty.	Production Qty.	Closing Qty.	Opening Qty.	Production Qty.	Closing Qty.
Tablet (Pcs.)	16,521,477	55,676,345	13,311,461	18,027,802	90,358,200	16,521,477
Capsule (Pcs.)	6,418,438	2,990,324	4,442,518	5,712,396	25,625,500	6,418,438
Liquid (PHs.)	172,708	696,030	143,454	175,758	1,381,700	172,708
Dry Syrup (PHs)	139,868	231,280	42,850	144,313	1,247,800	139,868
<b>Total</b>	<b>23,252,491</b>	<b>59,593,979</b>	<b>17,940,283</b>	<b>24,060,269</b>	<b>118,613,200</b>	<b>23,252,491</b>



II. Disclosure as per requirement of Schedule XI, Part II, Note-5 of Para 3, of the Companies Act, 1994 are given below:

**Employee Position of SILVA PHARMACEUTICALS LTD. as at June 30, 2025**

	Total Employee	Officer & Staff		Worker & Employee	
		Head Office	Factory	Field	Factory
Number of Employees whose salary below taka 3,000 or 5,500 p.m.	-	-	-	-	-
Number of Employees whose salary above taka 3,000 or 5,500 p.m.	615	51	22	446	96
<b>Total for the year ended 30 June, 2025</b>	<b>615</b>	<b>51</b>	<b>22</b>	<b>446</b>	<b>96</b>
<b>For the year ended 30 June, 2024</b>	<b>596</b>	<b>51</b>	<b>26</b>	<b>418</b>	<b>101</b>

41.04 Disclosure as per requirement of schedule XI, part II, Para 4 of the Companies Act, 1994 are given below:

Payment to directors within the year ending 30 June, 2025 is as follows:.

	June 30, 2025	June 30, 2024
(a) Managerial Remuneration paid or payable during the financial year to the directors, including managing directors, a managing agent or manager;	500,000	1,200,000
(b) Expenses reimbursed to the Managing Agent;	Nil	Nil
(c) Commission or Remuneration payable separately to a managing agent or his associate;	Nil	Nil
(d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.;	Nil	Nil
(e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year.;	Nil	Nil
(f) Any other perquisite or benefits in cash or in kind stating, approximate money value where practicable; (Board meeting fees)	393,750	421,875
(g) Other allowances and commission including guarantee commission.	Nil	Nil
(h) Pensions etc.		
(i) Pensions	Nil	Nil
(ii) Gratuities	Nil	Nil
(iii) Payments from a provident funds, in excess of own subscription and interest thereon	Nil	Nil
(iv) Compensation for loss of office	Nil	Nil
(v) Consideration in connection with retirement from office.	Nil	Nil



41.05 Disclosure as per requirement of schedule XI, Part II, Para 7 of the Companies Act, 1994 are given below:

Name of Item	Production Capacity		Yearly Production		Capacity Utilization ( % )	
	Million Pcs/Ph.		Million Pcs/Ph.			
	30-Jun-25	30-Jun-24	30-Jun-25	30-Jun-24	30-Jun-25	30-Jun-24
Tablet	200.00	200.00	55.68	90.36	27.84%	45.18%
Capsule	58.00	58.00	2.99	25.63	5.16%	44.19%
Liquid	2.00	2.00	0.70	1.38	34.80%	69.00%
Dry Syrup	1.80	1.80	0.23	1.25	12.85%	69.44%
<b>Total</b>	<b>261.80</b>	<b>261.80</b>	<b>59.59</b>	<b>118.62</b>	<b>22.76%</b>	<b>45.31%</b>

Note: Capacity is calculated considering 300 days per year; 2 shifts per day and 8 hours per shifts.

41.06 Disclosure as per requirement of schedule XI, part II, Para 8 of the Companies Act, 1994 are given below:

- a) Value of imports calculated on C.I.F basis by the company during the year ended 30 June, 2025 in respect of Raw materials, Component and Spare parts and Capital Goods were as follows:

S.L	Particulars	Import		
		Unit	Quantity	Amount in BDT
i	Raw Materials	Kg/Ltr.	60,198	9,919,906
ii	Packing Materials	Pcs/Kg	9,199	9,375,607
iii	Components of Spare parts	Set	-	-
iv	Capital Goods	Set	-	-
<b>Total</b>			<b>69,396</b>	<b>19,295,512</b>

- b) The Company did not have any expenditure in foreign currency during the year on account of Royalty, Know-how, Professional consultancy fees, Interest and other matters.
- c) Value of all imported raw materials, spare parts and components consumed during the financial year and the value of all indigenous raw materials, spare parts and components similarly consumed and the percentage of each to the total consumption were as follows:



Particulars	Imported Value (in BDT)	Imported in percentage (%)	Indigenous Value (in BDT)	Indigenous in percentage(%)	Total
Raw Materials	52,385,106	35.61%	94,707,077	64.39%	147,092,183
Packing Materials	12,444,111	27.06%	33,535,671	72.94%	45,979,782
Components and Spare parts	-	0.00%	11,498,902	100.00%	11,498,902
<b>Total</b>	<b>64,829,217</b>	<b>31.69%</b>	<b>139,741,651</b>	<b>68.31%</b>	<b>204,570,868</b>

- d) No amount has been remitted during the year in foreign currencies on account of dividend with a specific mention of the number of non-residents shareholders, the number of shares held by them on which the dividends were due and the year to which the dividends, related.
- e) Earnings in foreign exchange classified under the following heads as follows:
- No export made during the year;
  - No royalty, know-how, professional and consultation fees were received;
  - No Interest and Dividend received;
  - No Other income received

#### 42.00 Reconciliation of Net income with Cash Flows from Operating Activities

AS per Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: the Reconciliation of Net operating cash flow under Indirect Method is as follows:

Particulars	45,838	45,473
<b>Net Profit before Income tax</b>	<b>(119,579,426)</b>	<b>(46,496,645)</b>
<b>Adjustment for:</b>		
Depreciation	59,108,221	60,446,614
Amortization	190,903	136,071
Finance Expense for lease	454,922	833,331
	<b>59,754,046</b>	<b>61,416,016</b>
<b>Change in operating assets</b>		
Decrease (Increase) in Advances, deposits and Prepayments.	1,588,314	(2,531,443)
Decrease (Increase) in Trade & Other Receivable	26,512,423	3,188,964
Increase (Decrease) in Accounts and Other Payable	2,808,566	173,554
Increase (Decrease) in Provision and Accruals	(2,655,283)	(1,095,375)
Decrease (Increase) in Inventories	50,189,996	520,390
Income Tax Paid	(5,060,573)	(11,756,646)
<b>Net Cash Generated From Operating activities (indirect method)</b>	<b>13,558,063</b>	<b>3,418,815</b>
<b>Net Cash Generated From Operating activities (Direct method)</b>	<b>13,558,063</b>	<b>3,418,815</b>

#### 43.00 Disclosures as per IAS 24 Related Party disclosures are as follows:

The company carried out a number of transaction with related parties. The following are the related parties transactions of Silva pharmaceuticals Limited has been disclosed as required by IAS 24 Related Party Disclosures:



43.01 Disclosures as per paragraph 17 of IAS 24 are as follows:

(a) Short term employee benefits:

Name of the Related Parties	Nature of Relationship	Nature of Transaction	Value of goods/Services received during the year	Balance payable as on 30.06.2025
Dr. Saira Khan	Managing Director & Director	Remuneration	500,000	-
		Board Meeting Fees	18,750	-
Mrs. Silvana Mirza	Chairman	Board Meeting Fees	37,500	-
Mrs. Samina Mirza	Director	Board Meeting Fees	37,500	-
Mrs. Farhana Mirza	Director	Board Meeting Fees	28,125	-
Md. Monsur Rahman (Representative of Adarsha Fisheries & Poultry Farms Ltd.)	Director	Board Meeting Fees	93,750	-
AKM Nuruzzaman (Representative of ICB) from 14.11.2025	Director	Board Meeting Fees	9,375	-
Mrs. Mahmuda Akhter (Representative of ICB) Upto 14.11.2025	Director	Board Meeting Fees	18,750	-
A.T.M. Sarwar Kamal Chowdhury	Independent Director	Board Meeting Fees	84,375	-
Muhammad Moniruzzaman, FCA	Independent Director	Board Meeting Fees	65,625	-
Mr. A. R. Hassan Mirza	Executive Director & Sponsor Shareholder	Salary & Allowances	3,600,000	300,000
		Office Rent	1,593,720	132,810
<b>Total</b>			<b>6,087,470</b>	<b>432,810</b>

June 30, 2025

- (b) Post-employee benefits
- © Other long term benefits
- (d) Termination benefits and
- (e) Share-based payment

Nil  
Nil  
Nil  
Nil

44.00 **General:**

44.01 **Capital Expenditure Commitment:**

There was no capital expenditure contracted except contract for construction of new factory building using IPO fund as on 30.06.2025. and all material capital expenditure authorized by the board.

44.02 **Claim not Acknowledged as Debts:**

There is no claim against the company which have been acknowledged as debt as at 30 June, 2025.

44.03 **Commission, Brokerage or Discount:**

No brokerage or discount other than usual trade discount against sales was paid during the year. As there was no sales agent, commission therefore was not paid.

44.04 **Un-availed Credit Facilities:**

There are no credit facilities available to the company under any contract but not availed as on 30.06.2025 other than bank credit facility and trade credit available in ordinary course of business.

44.05 **Contingent Liabilities and Assets**

There was no contingent liability other than letters of credit outstanding for importation of raw and packing materials, capital goods as on 30.06.2025.



**Silva Pharmaceuticals Limited**  
**Schedule of Property, Plant and Equipment**  
As on 30 June, 2025

Particulars	Cost			Rate (%)	Depreciation			Amount in Taka	
	Balance as on 01 July, 2024	Addition during the year	Balance as on 30 June, 2025		Balance as on 01 July, 2024	Charge during the year	Balance as on 30 June, 2025	Written Down Value as at 30 June, 2025	
	Land & Land Development	342,774,940	-		342,774,940	0%	-	-	-
Plant & Machinery	692,749,945	-	692,749,945	10%	454,752,827	23,799,712	478,552,539	214,197,406	
Generator	12,396,170	-	12,396,170	10%	10,062,287	233,388	10,295,675	2,100,495	
Building Decoration	121,235,416	-	121,235,416	10%	62,229,162	5,900,625	68,129,787	53,105,629	
Electrical Installation	39,471,371	-	39,471,371	10%	17,966,036	2,150,534	20,116,570	19,354,801	
Gas Installation	389,890	-	389,890	10%	321,650	6,824	328,474	61,416	
Office Equipment	58,689,497	-	58,689,497	10%	31,068,853	2,762,064	33,830,917	24,858,580	
Factory Equipment	64,741,123	72,450	64,813,573	10%	35,526,245	2,921,488	38,447,733	26,365,840	
Furniture and Fixture	49,486,298	-	49,486,298	10%	30,177,110	1,930,919	32,108,029	17,378,269	
Vehicle	129,904,291	-	129,904,291	20%	109,305,717	4,119,715	113,425,432	16,478,859	
Power House	1,195,705	-	1,195,705	10%	996,894	19,881	1,016,775	178,930	
Laboratory Equipment	99,725,018	-	99,725,018	10%	43,060,321	5,666,470	48,726,791.0	50,998,227	
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	91,217,538	8,321,802	99,539,340	324,550,279	
<b>Total as on 30 June, 2025</b>	<b>2,036,849,283</b>	<b>72,450</b>	<b>2,036,921,733</b>		<b>886,684,640</b>	<b>57,833,422</b>	<b>944,518,062</b>	<b>1,092,403,671</b>	

01 July 2024 to 30 June 2025
57,833,422

<b>Allocation of Depreciation</b>
Charged during the year
Adjustment during the year

(a) Depreciation charged to cost of sales (Note-22.00)	57,833,422
(b) Depreciation charged to administrative expenses (Note-23.00)	53,785,083
(c) Depreciation charged to selling & distribution expenses (Note-24.00)	3,470,005
<b>Total</b>	57,833,422



**Schedule of Property, Plant and Equipment**  
As on 30 June, 2024

Particulars	Amount in Taka						
	Cost			Depreciation		Written Down Value as at 30 June, 2024	
	Balance as on 01 July, 2023	Addition during the year	Balance as on 30 June, 2024	Rate (%)	Balance as on 01 July, 2023		Charge during the year
Land & Land Development	342,774,940	-	342,774,940	0%	-	-	342,774,940
Plant & Machinery	636,753,992	55,995,953	692,749,945	10%	433,490,672	21,262,155	454,752,827
Generator	12,396,170	-	12,396,170	10%	9,802,967	259,320	10,062,287
Building Decoration	121,235,416	-	121,235,416	10%	55,672,911	6,556,251	62,229,162
Electrical Installation	39,471,371	-	39,471,371	10%	15,576,554	2,389,482	17,966,036
Gas Installation	389,890	-	389,890	10%	314,068	7,582	321,650
Office Equipment	58,230,177	459,320	58,689,497	10%	28,028,885	3,039,968	31,068,853
Factory Equipment	64,364,865	376,258	64,741,123	10%	32,294,236	3,232,009	35,526,245
Furniture and Fixture	49,393,811	92,487	49,486,298	10%	28,035,108	2,142,002	30,177,110
Vehicle	129,904,291	-	129,904,291	20%	104,156,073	5,149,644	109,305,717
Power House	1,195,705	-	1,195,705	10%	974,804	22,090	996,894
Laboratory Equipment	97,865,638	1,859,380	99,725,018	10%	36,867,825	6,192,496	43,060,321
Factory Building & Warehouse	424,089,619	-	424,089,619	2.5%	82,682,356	8,535,182	91,217,538
<b>Total as on 30 June, 2024</b>	<b>1,978,065,885</b>	<b>58,783,398</b>	<b>2,036,849,283</b>		<b>827,896,459</b>	<b>58,788,181</b>	<b>886,684,640</b>

**Allocation of Depreciation**

Charged during the year  
Adjustment during the year

- (a) Depreciation charged to cost of sales (Note-22.00)
- (b) Depreciation charged to administrative expenses (Note-23.00)
- (c) Depreciation charged to selling & distribution expenses (Note-24.00)

**Total**

01 July 2023 to 30 June 2024	58,788,181
<b>58,788,181</b>	<b>58,788,181</b>
54,673,008	3,527,291
587,882	<b>58,788,181</b>



**Silva Pharmaceuticals Limited**  
**Schedule of Property, Plant and Equipment (Tax Base)**  
**As on 30 June, 2025**

Particulars	Cost				Rate (%)	Depreciation			Amount in Taka	
	Balance as on 01 July, 2024	Addition during the year	Balance as on 30 June, 2025	Charge during the year		Balance as on 01 July, 2024	Charge during the year	Balance as on 30 June, 2025	Written Down Value as at 30 June, 2025	
Land & Land Development	342,774,940	-	342,774,940	-	0%	-	-	-	342,774,940	
Plant & Machinery	692,749,945	-	692,749,945	-	20%	589,997,835	20,550,422	610,548,257	82,201,688	
Generator	12,396,170	-	12,396,170	-	20%	12,009,381	77,358	12,086,739	309,431	
Building Decoration	121,235,416	-	121,235,416	-	20%	95,284,221	5,190,239	100,474,460	20,760,956	
Electrical Installation	39,471,371	-	39,471,371	-	20%	30,126,901	1,868,894	31,995,795	7,475,576	
Gas Installation	389,890	-	389,890	-	20%	379,967	1,985	381,952	7,938	
Office Equipment	60,598,717	1,387,800	61,986,517	1,387,800	20%	46,918,839	3,013,536	49,932,375	12,054,142	
Factory Equipment	64,741,123	72,450	64,813,573	72,450	10%	37,172,815	2,764,076	39,936,891	24,876,682	
Furniture and Fixture	49,486,298	-	49,486,298	-	10%	31,112,598	1,837,370	32,949,968	16,536,330	
Vehicle	129,904,291	-	129,904,291	-	20%	111,800,443	3,620,770	115,421,213	14,483,078	
Power House	1,195,705	-	1,195,705	-	20%	1,164,369	6,267	1,170,636	25,069	
Laboratory Equipment	99,725,018	-	99,725,018	-	20%	68,251,352	6,294,733	74,546,085	25,178,933	
Factory Building & Warehouse	424,089,619	-	424,089,619	-	10%	266,545,440	15,754,418	282,299,858	141,789,761	
<b>Total as on 30 June, 2025</b>	<b>2,038,758,503</b>	<b>1,460,250</b>	<b>2,040,218,753</b>	<b>1,460,250</b>		<b>1,290,764,161</b>	<b>60,980,068</b>	<b>1,351,744,229</b>	<b>688,474,524</b>	



**Schedule of Property, Plant and Equipment (Tax Base)**  
As on 30 June, 2024

Particulars	Amount in Taka					
	Cost			Depreciation		Written Down Value as at 30 June, 2024
	Balance as on 01 July, 2023	Addition during the year	Balance as on 30 June, 2024	Rate (%)	Balance as on 01 July, 2023	
Land & Land Development	342,774,940	-	342,774,940	0%	-	342,774,940
Plant & Machinery	636,753,992	55,995,953	692,749,945	20%	564,309,808	102,752,110
Generator	12,396,170	-	12,396,170	20%	11,912,684	386,789
Building Decoration	121,235,416	-	121,235,416	20%	88,796,422	25,951,195
Electrical Installation	39,471,371	-	39,471,371	20%	27,790,784	9,344,470
Gas Installation	389,890	-	389,890	20%	377,486	9,923
Office Equipment	60,139,397	459,320	60,598,717	20%	43,498,870	13,679,878
Factory Equipment	64,364,865	376,258	64,741,123	10%	34,109,670	27,568,308
Furniture and Fixture	49,393,811	92,487	49,486,298	10%	29,071,076	18,373,700
Vehicle	129,904,291	-	129,904,291	20%	107,274,481	18,103,848
Power House	1,195,705	-	1,195,705	20%	1,156,535	31,336
Laboratory Equipment	97,865,638	1,859,380	99,725,018	20%	60,382,936	31,473,666
Factory Building & Warehouse	424,089,619	-	424,089,619	10%	249,040,531	157,544,179
<b>Total as on 30 June, 2024</b>	<b>1,979,975,105</b>	<b>58,783,398</b>	<b>2,038,758,503</b>		<b>1,217,721,283</b>	<b>747,994,342</b>



**Silva Pharmaceuticals Limited**  
**Schedule of Intangible Assets**  
**As on 30 June, 2025**

Particulars	Cost			Rate (%)	Amortization			Amount in Taka	
	Balance as on 01 July, 2024	Addition during the year	Balance as on 30 June, 2025		Balance as on 01 July, 2024	Charge during the year	Balance as on 30 June, 2025	Written Down Value as at 30 June, 2025	Balance as on 30 June, 2025
									Balance as on 30 June, 2025
Software	1,909,220	1,387,800	3,297,020	10%	684,582	190,903	875,485	2,421,535	
<b>Total as on 30 June, 2025</b>	<b>1,909,220</b>	<b>1,387,800</b>	<b>3,297,020</b>		<b>684,582</b>	<b>190,903</b>	<b>875,485</b>	<b>2,421,535</b>	
<b>Total as on 30 June, 2024</b>	<b>1,909,220</b>	<b>-</b>	<b>1,909,220</b>		<b>548,511</b>	<b>136,071</b>	<b>684,582</b>	<b>1,224,638</b>	

Allocation of Amortization	
Charged during the year	190,903
Adjustment during the year	136,071
<b>Total</b>	<b>190,903</b>

01 July 2024 to 30 June 2025		01 July 2023 to 30 June 2024	
Charged during the year	190,903	190,903	136,071
Adjustment during the year	-	190,903	136,071
<b>Total</b>	<b>190,903</b>	<b>190,903</b>	<b>136,071</b>

Amortization charged to administrative expenses (Note-23.00)



**Silva Pharmaceuticals Limited**  
**Schedule of Right of Use Assets (RoU)**  
**As on 30 June, 2025**

Right-of-use assets (ROU) arise due to implementation of IFRS 16 from 1st July 2019. This is made up from use of building as lease of Corporate Office, Factory and Depot Offices.

Particulars	Cost		Depreciation			Written Down Value as at 30 June, 2025	
	Balance as on 01 July, 2024	Addition during the year	Balance as on 30 June, 2025	Balance as on 01 July, 2024	Charge during the year		Balance as on 30 June, 2025
Right of Use Assets (RoU)	26,266,197	-	26,266,197	20,614,235	1,274,799	21,889,034	4,377,163
<b>Total as on 30 June, 2025</b>	<b>26,266,197</b>	<b>-</b>	<b>26,266,197</b>	<b>20,614,235</b>	<b>1,274,799</b>	<b>21,889,034</b>	<b>4,377,163</b>
<b>Total as on 30 June, 2024</b>	<b>26,266,197</b>	<b>-</b>	<b>26,266,197</b>	<b>18,955,802</b>	<b>1,658,433</b>	<b>20,614,235</b>	<b>5,651,962</b>

Right-of-use assets (ROU) arise due to implementation of IFRS 16 from 1st July 2019. This is made up from use of building as lease of Corporate Office, Factory and Depot Offices.

Allocation of Depreciation	
Charged during the year	1,274,799
Adjustment during the year	1,658,433
<b>Total</b>	<b>1,658,433</b>

01 July 2024 to 30 June 2025	01 July 2023 to 30 June 2024
1,274,799	1,658,433
<b>1,274,799</b>	<b>1,658,433</b>
<b>1,274,799</b>	<b>1,658,433</b>
<b>1,274,799</b>	<b>1,658,433</b>

Depreciation charged to administrative expenses (Note-23.00)

**Total**

